Vanguard Group Inc Morphic Holding, Inc. Transaction History

Vanguard Group Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$26.12 - $34.07 $1.18 Million - $1.54 Million	-45,246 Reduced 2.0%	2,215,949 $75.5 Million
Q1 2024 May 10, 2024	SELL	$26.64 - $40.31 $1.59 Million - $2.41 Million	-59,851 Reduced 2.58%	2,261,195 $79.6 Million
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $4.26 Million - $6.62 Million	213,636 Added 10.14%	2,321,046 $67 Million
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $4.28 Million - $11.9 Million	200,772 Added 10.53%	2,107,410 $48.3 Million
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $7.41 Million - $13.4 Million	215,820 Added 12.76%	1,906,638 $109 Million
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $531,696 - $995,320	20,442 Added 1.22%	1,690,818 $63.6 Million
Q4 2022 Feb 10, 2023	BUY	$24.14 - $30.37 $5.28 Million - $6.64 Million	218,669 Added 15.06%	1,670,376 $44.7 Million
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $2.78 Million - $4.17 Million	124,861 Added 9.41%	1,451,707 $41.1 Million
Q2 2022 Aug 12, 2022	BUY	$19.74 - $43.01 $1.75 Million - $3.8 Million	88,432 Added 7.14%	1,326,846 $28.8 Million
Q1 2022 May 13, 2022	BUY	$36.25 - $52.02 $1.49 Million - $2.14 Million	41,094 Added 3.43%	1,238,414 $49.7 Million
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $445,205 - $676,193	10,289 Added 0.87%	1,197,320 $56.7 Million
Q3 2021 Nov 12, 2021	BUY	$53.61 - $67.5 $11.3 Million - $14.2 Million	210,472 Added 21.55%	1,187,031 $67.2 Million
Q2 2021 Aug 13, 2021	BUY	$45.13 - $64.99 $44.1 Million - $63.5 Million	976,559 New	976,559 $56 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.